By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

SillaJen 



  Busan    Korea
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
SillaJen Announces Collaboration With The NCI For Development Of Combination Therapy With SillaJen's Pexastimogene Devacirepvec (Pexa-Vec) Oncolytic Immunotherapy 8/17/2017 6:18:23 AM
SillaJen And Lee's Pharmaceutical Announce Approval By The China CFDA To Commence Phase III Clinical Trial For Oncolytic Immunotherapy, Pexa-Vec, In Liver Cancer 7/21/2017 6:40:09 AM
Regeneron (REGN) And SillaJen Announce Immuno-Oncology Clinical Study Agreement For Combination Treatment In Kidney Cancer 5/8/2017 6:59:42 AM
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/25/2017 12:38:06 PM
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/24/2017 9:57:14 AM
ASCO2016: SillaJen Announces Poster Presentation At ASCO Annual Meeting 5/31/2016 9:24:27 AM
SillaJen Announces Commercial Manufacturing Agreement With ABL Europe For Lead Oncolytic Virus, Pexa-Vec 5/16/2016 7:34:10 AM
SillaJen Enrolls First U.S. Patient In Multinational Phase 3 Trial For Pexa-Vec In Advanced Liver Cancer 3/29/2016 7:26:38 AM
Medivate Partners Invests $12 Million In SillaJen 3/21/2016 6:24:54 AM
SillaJen Announces First Patient Randomized In Multinational Phase 3 Trial For Pexa-Vec In Advanced Liver Cancer 1/6/2016 6:54:16 AM
12
//-->